본문 바로가기

company

History

Creating a bright future through challenges and changes.

Global Expansion ( 2011~ )

2023
  • ISO 9001 certification
  • NK Vue® Kit approval in China
2022
  • SuperNK® approved for phase 1/2a clinical trial in Korea [Allogeneic, metastatic gastric cancer]
  • SuperNK® approved for phase 1/2a clinical trial in the U.S [Allogeneic, solid cancer]
  • Signed MOU for Parkinson’s Foundation in the U.S.
  • Acceptance of SuperNK® clinical data poster at American Society of Clinical Oncology(ASCO),
    European Society for Medical Oncology(ESMO)
2021
  • SuperNK® approved for phase 1/2a clinical trial in Korea [EGFR-TKI resistant NSCLC]
  • SuperNK® phase 1/2a clinical trial completed in Korea
    [Stage IV NSCLC; combination of Immune checkpoint Inhibitors]
  • The name of the U.S. subsidiary changed to “NKGen Biotech”
  • NK Vue® Kit approval in Australia
  • Patent registration completed for NK Vue® Kit (1 patent, abroad)
  • Acceptance of SuperNK® clinical data poster at Society
    for Immunotherapy of Cancer(SITC), Connective Tissue Oncology Society(CTOS)
2020
  • Acceptance of SuperNK® clinical data poster at American Society
    of Clinical Oncology(ASCO), American Association for Cancer Research(AACR)
  • Signed a joint development agreement with Affimed NV
    for targeted NK cell therapy [SNK01-AFM24]
  • Protocol amendment approved for SuperNK® Phase
    I clinical trial in the U.S.
    [Refractory solid tumors; combination of immune
    checkpoint inhibitors]
  • SuperNK® approved for phase 1/2a clinical trial in the U.S.
    [Solid cancer; combined with targeted anticancer drugs]
  • SuperNK® approved for phase 1 clinical trial in Mexico
    [Alzheimer’s disease]
  • NK Vue® Kit approval in Slovakia
  • Patent registration completed for SuperNK® (1 patent, abroad)
  • Patent registration completed for NK Vue® Kit (17 patents, abroad)
2019
  • Merge of ATGen and NKMAX Co., Ltd.,
    Changed the company name to “NKMAX”
  • SuperNK® approved for phase 1 clinical trial in the U.S [Refractory Cancer]
  • SuperNK® approved for phase 1/2a clinical trial in Korea [Non-small cell lung cancer]
  • Patent registration completed for NK Vue® Kit (4 patents, abroad)
  • Completion of the U.S. GMP facilities
2018
  • NK Vue® Kit approval in Indonesia, Kazakhstan, and Singapore
  • NK Vue® Kit supply agreement signed with major Canadian diagnostics laboratories (Dynacare)
  • Patent registration completed for NK Vue® Kit (5 patents, abroad)
  • Patent registration completed for SuperNK (2 patents, abroad)
2017
  • NK Vue® Kit supply agreement signed with the U.S., Indonesia, and Kazakhstan
  • NK Vue® Kit approval in Thailand / public reimbursement in Türkiye
  • Patent registration completed for NK Vue® Kit (2 patents, abroad)
  • Set up a corporation office in the U.S. (NKMAX America) and Japan (NKMAX Japan)
2016
  • Patent acquisition for SuperNK® [NK cell culture and treatment technology]
  • ATGen H&D, an ATGen subsidiary company, was founded
  • NKMAX, an ATGen affiliate company, was founded
  • NK Vue® Kit public reimbursement in Korea
  • Patent registration completed for NK Vue® Kit (2 patents, abroad)
  • Completion of Korea GMP facilities
2015
  • ATGen listed on KOSDAQ with a special case of technology
2014
  • Set up a corporation office in Canada (ATGen Canada)
  • Europe CE marking, KGMP and Canada ISO 13485 certification
  • New Health Technology Assessment(nHTA) in Korea (NK Vue® Kit)
  • NK Vue® Kit approval in Canada
  • Patent registration completed for NK Vue® Kit (1 patent, Korea)
2013
  • Selected as promising SME by Gyeonggi Province
  • ISO 13485 certification
  • Patent registration completed for NK Vue® Kit (1 patent, Korea)
2012
  • Overseas revenue $1M
  • PCT Patent registration for NK Vue® Kit (1 patent)
  • NK Vue® Kit approval in Korea KMFDS

Growth ( 2006 - 2010 )

2009
  • Developed test kit for influenza enzyme linked immunosorbent assay
  • Established Direct online sales system
2007
  • INNO-BIZ Certified
2006
  • Designated as a Promising Export Company
  • Patent registration completed for SP fusion technology (1 patent, Korea / 1 patent, abroad)

Building Foundation ( Start - 2005 )

2005
  • Patent registration completed for SP fusion technology (3 patents, Korea / 1 patent, abroad)
2004
  • Patent registration completed for SP fusion technology (1 patent, Korea)
2003
  • R&D center certification
2002
  • Venture Company Certification
  • Founded ATGen

Move to Top